KRAS and acute myeloid leukemia: Given the encouraging results in OCI-AML3 cells, we compared the ex vivo activity of TP-0903 and gilteritinib in human primary samples with RAS (NRAS, KRAS, and PTPN11) mutations, along with other mutations frequently found in patients representing the clonal heterogeneity observed in AML.